LexDanaLexDanabeta
Inventor

Gilles Gosselin

Inventor
Montpellier, FR

Overview

58→
Patents
1984–2019
Patent span
Human necessities
Primary field (CPC A)

Patents· 58 as inventor

Public. Assignee & technology derived from the patent record. Each patent links to its LexDana page.

C07Hprimary
C07HSugars31%
A61PSpecific therapeutic activity of chemical compounds or medicinal preparations29%
A61KPreparations for medical, dental or toiletry purposes26%
C07FAcyclic, carbocyclic or heterocyclic compounds containing elements other than carbon, hydrogen, halogen, oxygen, nitrogen, sulfur, selenium or tellurium9%
C07KPeptides2%
C07DHeterocyclic compounds1%
Y02PClimate change mitigation technologies in the production or processing of goods1%
C07JSteroids1%
PatentTitleYear
10,513,5342'-chloro nucleoside analogs for HCV infection201910,238,680D-amino acid phosphoramidate pronucleotides of halogeno pyrimidine compounds for liver disease201910,231,986Amino acid phosphoramidate pronucleotides of 2'-cyano, azido and amino nucleosides for the treatment of HCV201910,202,4113'-substituted methyl or alkynyl nucleosides nucleotides for the treatment of HCV201910,005,7791',4'-thio nucleosides for the treatment of HCV20189,403,863'Substituted carbonyloxymethylphosphoramidate compounds and pharmaceutical compositions for the treatment of viral infections'20169,309,275'3′-deoxy nucleosides for the treatment of HCV'20169,296,778'3′,5′-cyclic phosphate prodrugs for HCV infection'20169,290,533'β-L-2′-deoxy-nucleosides for the treatment of hepatitis B'20169,249,173'Compounds and pharmaceutical compositions for the treatment of viral infections'20169,243,025'Compounds and pharmaceutical compositions for the treatment of viral infections'20169,211,300'4′-fluoro nucleosides for the treatment of HCV'20159,186,369'Purine nucleoside analogues for treating flaviviridae including hepatitis C'20158,742,101'Purine nucleoside analogues for treating flaviviridae including hepatitis C'20148,691,788'Compounds and pharmaceutical compositions for the treatment of viral infections'20148,680,071'Compounds and pharmaceutical compositions for the treatment of viral infections'20148,637,475'Modified 2′ and 3′ nucleoside prodrugs for treating flaviviridae infections'20147,951,789'Compounds and pharmaceutical compositions for the treatment of viral infections'20117,902,202'Compounds and pharmaceutical compositions for the treatment of viral infections'20117,795,238'β-L-2′-deoxy-nucleosides for the treatment of hepatitis B'20107,662,798'2′ and 3′-nucleoside prodrugs for treating Flaviviridae infections'20107,635,689'Modified 2′ and 3′-nucleoside prodrugs for treating Flaviviridae infections'20097,625,875'2′ and 3′-nucleoside prodrugs for treating Flaviviridae infections'20097,608,600'Modified 2′ and 3′-nucleoside prodrugs for treating Flaviviridae infections'20097,585,851'3′-prodrugs of 2′-deoxy-β-L-nucleosides'20097,582,618'2′-C-methyl-3′-O-L-valine ester ribofuranosyl cytidine for treatment of flaviviridae infections'20097,547,704'Modified 2′ and 3′-nucleoside prodrugs for treating Flaviviridae infections'20097,468,357'Nucleosides with anti-hepatitis B virus activity'20087,456,155'2′-C-methyl-3′-O-L-valine ester ribofuranosyl cytidine for treatment of flaviviridae infections'20087,439,351'2′ or 3′ -deoxy and 2′, 3′-dideoxy-β-L-pentofuranonucleo-side compounds, method of preparation and application in therapy, especially as anti-viral agents'20087,384,924'Modified 2′ and 3′-nucleoside prodrugs for treating Flaviviridae infections'20087,365,057'Modified 2′ and 3′-nucleoside prodrugs for treating Flavivridae infections'20087,304,043'β-L-2′-deoxy-nucleosides for the treatment of hepatitis B'20077,192,936'Modified 2′ and 3′-nucleoside prodrugs for treating Flaviviridae infections'20077,138,376'Methods and compositions for treating hepatitis C virus using 4\'-modified nucleosides'20067,045,309'9-substituted adenine derivatives as prodrug regulators of cell and tissue function'20066,946,450'β-L-2′-deoxy-nucleosides for the treatment of hepatitis B'20056,896,900'β-L-2\'-deoxy-nucleosides for the treatment of HIV infection'20056,875,751'3′-prodrugs of 2′-deoxy-β-L-nucleosides'20056,569,837'-L-2-deoxy pyrimidine nucleosides for the treatment of hepatitis B'20036,566,344'-L-2-deoxy-nucleosides for the treatment of hepatitis B'20036,555,676'Biologically active phosphotriester-type compounds'20036,525,033'Nucleosides with anti-hepatitis B virus activity'20036,458,773'Nucleoside with anti-hepatitis B virus activity'20026,444,652'-L-2\'-deoxy-nucleosides for the treatment of hepatitis B'20026,407,077'-L nucleosides for the treatment of HIV infection'20026,399,589'Biologically active phosphotriester-type compounds'20026,395,716'-L-2-deoxy-nucleosides for the treatment of hepatitis B'20026,245,749'Nucleosides with anti-hepatitis B virus activity'20016,124,445'Phosphotriester oligonucleotides, amidities and method of preparation'20006,020,482'Phosphotriester type biologically active compounds'20005,990,093'Treating HBV with phospholipid prodrugs of .beta.-L-2\',3\'-dideoxyadenosine 5\'-monophosphate'19995,955,591'Phosphotriester oligonucleotides, amidites and method of preparation'19995,849,905'Biologically active phosphotriester-type nucleosides and methods for preparing same'19985,770,725'Phosphotriester type biologically active compounds'19985,627,185'Acyclovir derivatives as antiviral agents'19974,659,698'Pharmaceutical compositions based on xylosides and lyxosides of purine and pyrimidine bases used in a method of treating viruses'19874,476,301'Oligonucleotides, a process for preparing the same and their application as mediators of the action of interferon'1984

Career & activity timeline

Assembled from patent assignee/location history and declaration credentials.

1984–2019Patents assigned to CENTRE NAT RECH SCIENT (35)· patent assignee history
1984–2019Based in Montpellier, FR· patent location history
1998Based in Rue Paul-Rimbaud - 34000 Montpellier, FR· patent location history
2003–2016Patents assigned to IDENIX PHARMACEUTICALS INC (26)· patent assignee history
2005–2016Patents assigned to UNIV MONTPELLIER II (19)· patent assignee history
2007–2014Patents assigned to UNIV CAGLIARI (11)· patent assignee history
2007–2014Based in Monpellier, FR· patent location history
2015–2019Patents assigned to IDENIX PHARMACEUTICALS LLC (11)· patent assignee history

Inventor activity

Assignee and location history derived from the patent record.

Assignees
AssigneePatentsSpan
CENTRE NAT RECH SCIENT351984–2019
IDENIX PHARMACEUTICALS INC262003–2016
UNIV MONTPELLIER II192005–2016
IDENIX PHARMACEUTICALS LLC112015–2019
UNIV CAGLIARI112007–2014
Locations
LocationPatentsSpan
Montpellier, FR491984–2019
Monpellier, FR82007–2014
Rue Paul-Rimbaud - 34000 Montpellier, FR11998